The FDA is seeking public feedback on plans to tailor rare disease drug development and regulatory review to small patient populations and the evidence they can realistically generate.

New framework targets rare disease development challenges

The US Food and Drug Administration (FDA) has launched an initiative to develop a new framework for reviewing medicines for rare diseases, aiming to improve consistency and predictability while maintaining standards for safety and effectiveness.

Announced on 14 October, the Rare Disease Framework Initiative will consider the characteristics of individual diseases, patient needs, the type of product being developed and the evidence that can reasonably be generated when patient populations are small.

The FDA said around 5% of rare conditions have an approved treatment in the US, highlighting the need to improve the development of medicines for people with limited therapeutic options.

The initiative will be led by the FDA’s Rare Disease Innovation Hub, working with the Office of the Commissioner, the Center for Biologics Evaluation and Research and the Center for Drug Evaluation and Research.

Patient input and scientific methods among priorities

The FDA has identified several priorities for the proposed framework, including clearer regulatory guidance, more consistent decision-making and greater involvement of patients and families at key stages of drug development and review.

The agency also plans to explore greater use of external expertise, shared resources and staff training to support reviews of rare disease therapies. Other priorities include risk-based approaches to chemistry, manufacturing and controls assessments, alongside the use of new scientific methods, clinical trial designs and statistical approaches.

These measures are intended to reflect the challenges of generating evidence in small populations, where conventional clinical development approaches may be difficult to apply.

Amy Comstock Rick, director of the Rare Disease Innovation Hub, said: “Patients with rare diseases and their families deserve a regulatory process that addresses the uniqueness of each of their conditions while maintaining the FDA’s rigorous standards.”

She added: “This new framework will enhance consistency and predictability for both sponsors and for patients.”

Public meeting to inform next steps

The FDA will seek feedback from patients, disease advocates, industry and other stakeholders at a public meeting on 28 October at its White Oak campus in Maryland. The meeting will be facilitated by the Reagan-Udall Foundation for the FDA.

Further consultation is planned through sector-specific roundtables, requests for information and internal feedback sessions. Responses will help shape the framework, which could lead to new or revised guidance, regulatory changes, additional staff training and organisational changes.

The initiative remains at the development stage. The FDA has not yet announced a final framework or specific changes to approval requirements for rare disease medicines. Its stated aim is to make regulatory decisions more tailored to individual diseases and development programmes while maintaining standards for drug quality, safety and effectiveness.